STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

NVCR NOVOCURE StockScouter® Report

4

StockScouter® Score

NOVOCURE, a small cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • Shares are under accumulation by financial institutions. Marginally positive for a small company like NVCR

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative
  • Moving average analysis for NVCR suggests weak price movement over the medium term. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 80% done.
Progress: 60% done.
Low
High

Core Model Grades

C
D
C
F

Previous Ratings

5
4
2